Skip to content
Dr Charles Heard

Dr Charles Heard

Reader

School of Pharmacy and Pharmaceutical Sciences

Email:
heard@cardiff.ac.uk
Telephone:
+44 (0)29 2087 5819
Fax:
+44 (0)29 2087 4149
Media commentator

Dr Heard has 30 years of experience in investigating novel topical drug delivery systems and determining their biological effects. During this time he has published 95 papers and attracted funding of approximately £2M, with recent successes including 2x Welsh Government Life Sciences bridging fund awards. He has has engaged extensively with the research translation processes towards the commercialisation of new products, in particular skin disinfection and wound healing.

Chair, Research Committee - Cardiff Institute of Tissue Engineering and Repair (CITER)

Career profile

  • 2016 - present, Reader in Pharmaceutical Chemistry, Cardiff University
  • 2007 – 2016, Senior Lecturer, Cardiff University , Group leader, Skin and Natural Products group
  • 1998 – 2007, Lecturer, Cardiff University
  • 1991 – 1997, PDRA, Cardiff University
  • 1987 – 1991, PhD student, Cardiff University
  • 1982 – 1987, Team leader, Amersham International

Scientific and professional service

Membership of: The Academy of Pharmaceutical Sciences; International Society for Skin Pharmacology and Physiology

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2000

1999

1997

1996

1995

1993

My teaching is largely in the areas of Pharaceutical Chemistry and and Formulation Science.

MODULE LEADER - PH2107 Formulation Science I

Member of the School's Drug Delivery & Microbiology Research Discipline

Research interest

Dr Heard has 30 years of experience in investigating novel topical drug delivery systems and determining their biological effects. During this time he has published 95 papers and attracted funding of approximately £2M, with recent successes including 2x Welsh Government Life Sciences bridging fund awards. He has has engaged extensively with the research translation processes towards the commercialisation of new products, in particular skin disinfection and wound healing. For example, his group is currently developing a novel controlled release, biocide-eluting patch for wound infected with antibiotic-resistant pathogenic microorganisms. This involves significant interaction with the University’s Technology Transfer Officers and Patent Attorneys in order to work towards securing protectable, IP. The work has been supported by MRC, BBSRC which also covered a sizeable outlay to cover the cost of market research and professional advice on developing a route to market. More recent efforts have focussed on the pathobiology of tissues of the eye, and the development of novel ocular drug delivery systems and novel products to treat periodontal diseases and responsive/smart cavity dressings. Exploitation of the microbicidal and anti-inflammatory properties of natural products, principally Punica granatum, is also a strong current theme.

Collaborators

  • Prof Keith Harding, School of Medicine
  • Prof Alastair Sloan, Prof David Williams, Dr Ryan Moseley: School of Dentistry
  • Profs Andrew Quantock and Marcela Votruba, Dr Malgorzata Rozanowska: School of Optometry and Vision Sciences
  • Dr Deborah Mason: School of Biosciences
  • Dr Andrea Brancale: School of Pharmacy and Pharmaceutical Sciences

Key expertise

  • Topical drug delivery, in vitro, ex vivo (skin, buccal, gingival, ocular)
  • Topical formulation development and evaluation
  • Pharmaceutical Analysis: HPLC, LCMS, Immunohistochemistry, ELISA
  • Natural product phytochemistry

Current

Submitted/Awarded

Supervisor role (lead, co-, 2nd)

AMAL ALRASHIDI FT

YR 3

LEAD

HANNAH BUNDY

YR 3

LEAD

CARMINE VARICCHIO

YR 3

CO-SUPERVISOR

BEN EGAN

YR 2

CO-SUPERVISOR

VILDAN CELIKSOY

YR 1

LEAD

AHMED YONBAWI

YR 1

LEAD

Areas of expertise